Fresenius Medical Care AG - Form 6-K Filing

This filing includes several exhibits, including press releases and notices regarding financial and operational updates for Fresenius Medical Care AG. Key highlights from the May 21, 2026 press release indicate a successful completion of the FME Reignite strategy, improved profitability, and an 8% organic revenue growth. The company approved a dividend of EUR 1.49 per share and completed a EUR 1 billion share buyback program, with a new authorization granted for future buybacks. The 5008X CAREsystem was introduced in U.S. clinics, with a full commercial launch planned for 2026. A subsequent press release on May 26, 2026, announced a new share buyback program of approximately EUR 1 billion over 12 months, underscoring the company's financial strength and commitment to shareholder value. The filing also includes notices regarding the authorization to exclude subscription rights for treasury shares and the cancellation of treasury shares to reduce share capital, reflecting adjustments to the company's capital structure.